Neoantigen Targeted Therapy Market By Therapy Type (Personalized Neoantigen Vaccines, T-cell Based Therapies); By Cancer Indication (Melanoma, NSCLC, Glioblastoma, Bladder Cancer, Colorectal Cancer, Others); By Delivery Platform (mRNA, Peptide, Dendritic Cell, DNA-based); By End User (Academic Medical Centers, Specialty Cancer Hospitals); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Neoantigen Targeted Therapy Market: Personalized Cancer Immunotherapy Moves From Concept to Recurrence-Risk Treatment (Last Updated on: June-2026)

The Global Neoantigen Targeted Therapy Market expanding at 28.4% CAGR, growing to USD 8.5 billion by 2030 from USD 1.9 billion in 2024.

 

The Neoantigen Targeted Therapy Market is a pipeline-driven precision oncology market built around one difficult promise of using each patient’s tumor mutations to train the immune system against cancer while sparing healthy tissue. Unlike shared tumor antigens, neoantigens arise from tumor-specific mutations, making them attractive targets for highly personalized cancer vaccines and engineered immune-cell therapies.

 

The market is not yet a broad commercial drug class. No patient-specific neoantigen therapy has full FDA approval as a standard marketed product. The category is being shaped by clinical validation, sequencing quality, antigen prediction, manufacturing speed, and the ability to fit personalized treatment into real oncology workflows.

 

Cancer burden provides the clinical base. Globally, there were close to 20 million new cancer cases and 9.7 million cancer deaths in 2022. In the United States, about 2.11 million new cancer cases and 626,140 cancer deaths are projected in 2026. Neoantigen therapy will not address all of these patients. Its strongest opportunity sits in cancers where tumor sequencing is routine, recurrence risk is high, and the treatment window allows enough time to design and manufacture a personalized therapy. [Wiley] [National Cancer Institute]

 

The market is being built around a smaller but higher-value treatment window encompassing patients whose tumors can be sequenced, whose relapse risk is clinically meaningful, and whose disease course allows sufficient time for a custom immune therapy to be designed and delivered.

 

Treatment Pathway and Patient Selection

Neoantigen therapy becomes relevant when tumor profiling can change the treatment plan. The pathway begins with tissue or blood-based testing, then moves into mutation selection, HLA matching, antigen prioritization, and product design.

The best near-term candidates are not all solid tumor patients. They are patients with high-risk resected melanoma, non-small cell lung cancer, pancreatic cancer, colorectal cancer, urothelial cancer, renal cell carcinoma, glioblastoma, and selected tumors where recurrence risk remains high after standard treatment.

Adjuvant and MRD-guided settings are the most practical early markets. These patients often have lower tumor burden and a clearer treatment window, giving personalized vaccines or neoantigen-directed immune therapies a better chance to work before visible relapse or rapid progression.

 

Neoantigen Targeted Therapy Market Segment Analysis

The strongest segment is individualized neoantigen vaccines. These therapies are built from each patient’s tumor mutation profile and are commonly delivered through mRNA, peptide, dendritic-cell, or viral-vector platforms. Intismeran autogene, formerly mRNA-4157/V940, is the most advanced program and is being studied with pembrolizumab in high-risk melanoma and other solid tumors.

Autogene cevumeran, also known as RO7198457/BNT122, is another major individualized mRNA neoantigen vaccine program. Its development in pancreatic cancer and ctDNA-positive colorectal cancer indicates the direction of the market, toward patients with high post-surgical recurrence risk, where immune priming may help delay relapse. [BioNTech]

Adoptive cell therapy and TCR-T approaches form the second major segment. These therapies use neoantigen-reactive T cells or engineered T-cell receptors to attack mutation-defined tumor targets. Lifileucel is not a patient-specific neoantigen product, but its FDA approval in advanced melanoma is an important adjacent precedent because tumor-infiltrating lymphocytes can naturally include neoantigen-reactive T cells. [National Institutes of Health]

Shared or semi-shared neoantigen approaches create a more scalable route. KRAS-directed vaccines such as ELI-002 target recurrent driver mutations rather than fully individualized mutation sets. This model is commercially attractive in pancreatic, colorectal, and lung cancers because it reduces customization burden while still targeting cancer-linked mutations.

Bispecific antibodies are conceptually relevant but less central to the current near-term market. The strongest clinical momentum remains in personalized vaccines, KRAS-directed vaccines, and neoantigen-reactive cellular therapies.

 

What Is Moving Neoantigen Therapy Adoption

Neoantigen therapy is being pulled by patients already inside precision oncology systems. The highest-value candidates are not unknown patients. They are already being sequenced, monitored after surgery, treated with checkpoint inhibitors, or tracked with ctDNA.

The most important shift is movement into recurrence-risk treatment. In high-risk resected melanoma, intismeran autogene plus pembrolizumab has shown durable recurrence-free survival and distant metastasis-free survival benefit versus pembrolizumab alone. This provides the market a clearer commercial path because adjuvant oncology has defined endpoints, established comparator therapy, and strong payer logic when relapse prevention is demonstrated.

Pancreatic and colorectal cancer create a different opportunity. These tumors are harder immunologically, but relapse risk after surgery is high. Programs such as autogene cevumeran and ELI-002 are testing whether immune targeting can work before bulky recurrent disease returns. If these programs succeed, the market could expand beyond traditionally immune-responsive cancers.

The main adoption barrier is operational. Personalized neoantigen therapy requires sequencing, bioinformatics, manufacturing, quality control, shipping, and clinical scheduling to work as one system. A strong immune response is not enough if the product arrives too late or if the oncology center cannot integrate the process into standard treatment timing.

 

Manufacturing and Bioinformatics Bottlenecks

Neoantigen therapy is as dependent on workflow quality as it is on immunology. Each individualized product depends on accurate mutation detection, HLA matching, neoepitope prediction, antigen expression, product design, and batch release.

This creates a major difference between companies. The strongest platforms will not simply identify more mutations. They will select better antigens, manufacture reliably, deliver within the treatment window, and generate durable CD4+ and CD8+ T-cell responses.

 

Competitive Landscape and Pipeline Direction

The market is led by companies that combine oncology biology, computational antigen selection, and scalable manufacturing. Moderna and Merck are the most visible players through intismeran autogene with pembrolizumab. BioNTech and Genentech remain important through autogene cevumeran. Elicio Therapeutics is relevant through KRAS-directed ELI-002. Other developers are working across peptide vaccines, dendritic-cell vaccines, viral-vector platforms, TCR-T therapy, TIL expansion, and AI-enabled neoantigen prediction. [Elicio Therapeutics]

Checkpoint inhibitor combinations will remain central. Neoantigen therapies can prime tumor-specific T cells, while PD-1 or PD-L1 blockade can help maintain antitumor activity in the tumor microenvironment. This makes the market more likely to expand as a combination immunotherapy category rather than a standalone vaccine class. [National Institutes of Health]

Approved adjacent products also shape expectations. Sipuleucel-T proved that personalized cellular immunotherapy can reach the market, although it targets a shared prostate cancer antigen rather than patient-specific mutations. Lifileucel proved that autologous T-cell therapy can be approved for a solid tumor. These precedents support the commercial logic of personalized immunotherapy, but they do not remove the need for neoantigen-specific late-stage proof. [National Cancer Institute]

 

Commercial Outlook

The Neoantigen Targeted Therapy Market is entering a clinical validation phase where immune response alone will not be enough. The next proof point is whether personalized or mutation-directed therapies can reduce recurrence, delay metastasis, or improve survival in clearly selected patients.

Near-term value will come from treatment settings where sequencing is already routine and relapse risk is measurable. This favors adjuvant melanoma, resected NSCLC, MRD-positive colorectal cancer, and KRAS-driven pancreatic cancer programs, but adoption will depend on late-stage efficacy and manufacturing reliability.

The category will be led by companies that can connect antigen prediction, product turnaround, checkpoint-combination strategy, and durable T-cell response into one workable oncology pathway. Neoantigen therapy remains early, but it is becoming one of the clearest examples of cancer treatment moving from tumor-type classification to patient-specific immune instruction.

 

Neoantigen Targeted Therapy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.9 Billion
Revenue Forecast in 2030	USD 8.5 Billion
Overall Growth Rate	CAGR of 28.4% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Therapy Type, By Cancer Indication, By Delivery Platform, By End User, By Geography
By Therapy Type	Personalized Neoantigen Vaccines, T-cell Based Therapies
By Cancer Indication	Melanoma, NSCLC, Glioblastoma, Bladder Cancer, Colorectal Cancer, Others
By Delivery Platform	mRNA, Peptide, Dendritic Cell, DNA-based
By End User	Academic Medical Centers, Specialty Cancer Hospitals
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, U.K., France, China, Japan, South Korea, Brazil, UAE
Market Drivers	• Increasing adoption of personalized cancer immunotherapy • Advancements in neoantigen prediction algorithms • Growing clinical evidence supporting neoantigen-based combinations
Customization Option	Available upon request